Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Series E Preferred Stock	Series F Preferred Stock	Class A and Class B Common Stock Class A and Class B Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Shares, beginning of period (in shares) at Jan. 31, 2020	113,523,948
Balance, beginning of period at Jan. 31, 2020	$ 201,826
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Preferred Stock, net of issuance costs (in shares)		31,405,183	22,128,982
Issuance of Preferred Stock, net of issuance costs		$ 152,539	$ 266,774
Shares, end of period (in shares) at Jan. 31, 2021	167,058,113
Balance, end of period at Jan. 31, 2021	$ 621,139
Shares, beginning of period (in shares) at Jan. 31, 2020				33,550,809
Balance, beginning of period at Jan. 31, 2020	(224,213)			$ 1	$ 8,986	$ (201)	$ (232,999)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)				5,358,692
Issuance of common stock upon exercise of options	4,608			$ 1	4,607
Issuance of common stock upon exercise of warrants (in shares)				321,802
Issuance of common stock upon exercise of warrants	200				200
Issuance of restricted stock for services provided (in shares)				11,013
Issuance of common stock for services provided	47				47
Vesting of early exercised options	71				71
Stock-based compensation	15,958				15,958
Foreign currency translation adjustments	366					366
Shares, end of period (in shares) at Jan. 31, 2021				39,242,316
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive loss	0
Net loss	(117,573)						(117,573)
Balance, end of period at Jan. 31, 2021	$ (320,536)			$ 2	29,869	165	(350,572)
Increase (Decrease) in Temporary Equity [Roll Forward]
Conversion of redeemable convertible preferred stock to common stock upon initial public offering (in shares)	(167,058,113)
Conversion of redeemable convertible preferred stock to common stock upon initial public offering	$ (621,139)
Shares, end of period (in shares) at Jan. 31, 2022	0
Balance, end of period at Jan. 31, 2022	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of redeemable convertible preferred stock to common stock upon initial public offering (in shares)				169,787,200
Conversion of redeemable convertible preferred stock to common stock upon initial public offering	621,139			$ 10	621,129
Issuance of common stock upon initial public offering and private placements, net of underwriting discounts and commissions (in shares)				41,678,568
Issuance of common stock upon initial public offering and private placements, net of underwriting discounts and commissions	1,380,960			$ 4	1,380,956
Issuance of common stock upon exercise of options (in shares)				9,793,331
Issuance of common stock upon exercise of options	14,621			$ 10	14,611
Issuance of common stock upon exercise of warrants (in shares)				940,953
Issuance of restricted stock for services provided (in shares)				20,000
Issuance of common stock for services provided	500				500
Vesting of restricted stock units (in shares)				15,218
Issuance of common stock under employee stock purchase plan (in shares)				381,716
Issuance of common stock under employee stock purchase plan	11,356				11,356
Vesting of early exercised options	572				572
Issuance of common stock and awards assumed in connection with acquisition (in shares)				7,277,214
Issuance of common stock and awards assumed in connection with acquisition	120,320			$ 1	120,319
Issuance of restricted stock awards (in shares)				1,315,099
Stock-based compensation	92,668				92,668
Foreign currency translation adjustments	289					289
Shares, end of period (in shares) at Jan. 31, 2022				270,451,615
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive loss	0
Net loss	(271,101)
Balance, end of period at Jan. 31, 2022	$ 1,650,788			$ 27	2,271,980	454	(621,673)
Shares, end of period (in shares) at Jan. 31, 2023	0
Balance, end of period at Jan. 31, 2023	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)				7,650,525
Issuance of common stock upon exercise of options	17,335			$ 1	17,334
Vesting of restricted stock units (in shares)				1,303,854
Issuance of common stock under employee stock purchase plan (in shares)				1,335,183
Issuance of common stock under employee stock purchase plan	19,159				19,159
Cancellation of holdback shares				(9,551)
Vesting of early exercised options	103				103
Issuance of common stock and awards assumed in connection with acquisition (in shares)				6,032,231
Issuance of common stock and awards assumed in connection with acquisition	186,333			$ 1	186,332
Stock-based compensation	168,486				168,486
Foreign currency translation adjustments	0
Shares, end of period (in shares) at Jan. 31, 2023				286,763,857
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive loss	(6,821)					(6,821)
Net loss	(378,678)						(378,678)
Balance, end of period at Jan. 31, 2023	$ 1,656,705			$ 29	$ 2,663,394	$ (6,367)	$ (1,000,351)